Compound: Omacetaxine mepesuccinate
SMILES: O=C(O[C@@H]1C(OC)=C[C@@]23[C@@H]1c4c(cc5OCOc5c4)CCN2CCC3)[C@](O)(CC(=O)OC)CCCC(O)(C)C
InChIKey: HYFHYPWGAURHIV-JFIAXGOJSA-N
Synonyms: Omacetaxine mepesuccinate, Ceflatonin, Myelostat, Synribo, CGX-635, Omapro, Homoharringtonin, (-)-homoharringtonine, NSC-141633, mepesuccinate d'omacetaxine, mepesuccinato de omacetaxina, CHEBI:71019, (2'R,3S,4S,5R)-(-)-homoharringtonine, omacetaxini mepesuccinas, 6FG8041S5B, 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate, Cephalotaxine 4-Methyl (2R)-2-Hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (Ester), Cephalotaxine, 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), DTXCID8025678, 1-((1S,3AR,14BS)-2-METHOXY-1,5,6,8,9,14B-HEXAHYDRO-4H-CYCLOPENTA(A)(1,3)DIOXOLO(4,5-H)PYRROLO(2,1-B)(3)BENZAZEPIN-1-YL) 4-METHYL (2R)-2-HYDROXY-2-(4-HYDROXY-4-METHYLPENTYL)BUTANEDIOATE, 1-[(1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-H]pyrrolo[2,1-b][3]benzazepin-1-yl] 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate, 1-O-((2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo(11.7.0.02,6.06,10.015,19)icosa-1(20),4,13,15(19)-tetraen-3-yl) 4-O-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate, RefChem:56718, L01XX40, DTXSID0045678, homoharringtonine, 26833-87-4, MFCD05618221, Omacetaxine (homoharringtonine), HHT, Omacetaxine mepesuccinate [USAN], NSC 141633, C29H39NO9, Cephalotaxine 4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate, Omacetaxine mepesuccinate (USAN), Tekinex, Synribo (TN), Omacetaxine mepesuccinate;HHT, UNII-6FG8041S5B, NSC141633, NCGC00025155-01, (2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0^{2,6}.0^{6,10}.0^{15,19}]icosa-1(13),4,14,19-tetraen-3-yl 1-methyl (3R)-3-hydroxy-3-(4-hydroxy-4-methylpentyl)butanedioate, (3beta)-O~3~-[(2r)-2,6-Dihydroxy-2-(2-Methoxy-2-Oxoethyl)-6-Methylheptanoyl]cephalotaxine, Omacetaxine mepesuccinate [USAN:INN], BRN 5687925, ZJ-C, Homoharringtonine (Standard), MLS001424293, CHEMBL46286, HOMOHARRINGTONINE [MI], CGX-635-14 (formulation), GTPL7454, SCHEMBL12745687, SCHEMBL30517017, GLXC-04527, HMS3267H22, HMS3414N05, HMS3678N03, MSK40305, Homoharringtonine, >=98% (HPLC), BDBM50480293, EBC-17148, HB4660, HY-14944R, NSC758253, s9015, Homoharringtonine - Bio-X trade mark, AKOS024456585, CCG-269981, DB04865, FH15974, NC00395, NSC-758253, OMACETAXINE MEPESUCCINATE [INN], NCGC00025155-02, NCGC00025155-03, NCGC00025155-04, NCGC00025155-07, OMACETAXINE MEPESUCCINATE [MART.], OMACETAXINE MEPESUCCINATE [VANDF], BH300085, HY-14944, NCI60_000917, OMACETAXINE MEPESUCCINATE [WHO-DD], SMR000469230, ST056357, H1775, NS00067000, D08956, OMACETAXINE MEPESUCCINATE [ORANGE BOOK], AB00642561-02, EN300-22161068, SR-01000597562, Q7089373, SR-01000597562-1, BRD-K76674262-001-01-7, BRD-K76674262-001-02-5, BRD-K76674262-001-03-3, Cephalotaxine, 3-[4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate], Cephalotaxine, 4-methyl-, 2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate (ester), (2S,3S,6S)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0<2,6>.0<6,10>.0<15,1 9>]icosa-1(20),4,13,15(19)-tetraen-3-yl methyl (2R)-2-hydroxy-2-(4-hydroxy-4-m ethylpentyl)butane-1,4-dioate, (S)-1-((11bS,12S,14aR)-13-methoxy-2,3,5,6,11b,12-hexahydro-1H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-12-yl) 4-methyl 2-hydroxy-2-(4-hydroxy-4-methylpentyl)succinate, 1-((11bS,12S,14aR)-13-Methoxy-2,3,5,6,11b,12-hexahydro-1H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-12-yl) 4-methyl (R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)succinate, 1-((1S,3aR,14bS)-2-Methoxy-1,5,6,8,9,14b-hexahydro-4H- cyclopenta(a)(1,3)dioxolo(4,5-h)pyrrolo(2,1-b)(3)benzazepin-1-yl) 4-methyl (2R)-2- hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate, O1-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] O4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methyl-pentyl)butanedioate
Theoretical properties:
molecular_formula: C29H39NO9
molecular_weight: 545.6 g/mol
exact_mass: 545.26248182 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 10
rotatable_bond_count: 11
heavy_atom_count: 39
topological_polar_surface_area: 124 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Omacetaxine mepesuccinate is a cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia. It has a role as an anticoronaviral agent, an antineoplastic agent, a protein synthesis inhibitor and an apoptosis inducer. It is a tertiary alcohol, an organic heteropentacyclic compound, an alkaloid ester and an enol ether. It is functionally related to a cephalotaxine.
chebi: A cephalotaxine-derived alkaloid ester obtained from <em>Cephalotaxus harringtonia</em>; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia.
chembl: OMACETAXINE MEPESUCCINATE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Omacetaxine mepesuccinate (INN; trade name Synribo; formerly named as homoharringtonine or HHT) is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML). Omacetaxine approval in US is discontinued (August 2024)[1][2] and is no longer recommended for treatment of CML (as of NCCN CML guidance 3.2025) [3].
HHT is a natural plant alkaloid derived from Cephalotaxus fortunei. HHT and related compound esters of cephalotaxine were described first in 1970, and were the subject of intensive research efforts by Chinese investigators to clarify their role as anticancer and antileukemic agents from the 1970s until the present.  It was approved by the US FDA in October 2012 for the treatment of adult patients with CML with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).